Toggle Offcanvas
...
 
Evolocumab Tenders

Evolocumab Tenders

View Evolocumab tenders, RFPs and contracts. Bid on readily available Evolocumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Evolocumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Evolocumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Evolocumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Evolocumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

8 Live Notices for Evolocumab Tenders

Showing 1 to 8

Medications Outside The List Of Drugs
country Serbia
posting date13 Mar 2025
deadline14 Apr 2025
Completion Of Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V For The Active Ingredient Evolocumab - Vv83
country Germany
posting date08 Mar 2025
deadline10 Feb 2027
Completion Of Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V For The Active Ingredient Evolocumab - Vv83
country Germany
posting date07 Mar 2025
deadline10 Feb 2027
Delivery Of Medicinal Products Used As Part Of Drug Programs
country Poland
posting date03 Mar 2025
deadline07 Apr 2025
Deruxtecan Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 160 MG Pharmaceutical Form: Injectable Lyophilized Powder; Crizotinib Concentration*: 250 MG; Enzalutamide Concentration: 40 MG; Ocrelizumab Concentration: 30 MG/ML Pharmaceutical Form: Solution for Infusion; Dapagliflozin Concentration: 10 MG; Evolocumab Concentration: 140 MG/ML Pharmaceutical Form: Injectable Solution Additional: With Applicator Pen; Ruxolitinib Concentration
country Brazil
posting date01 Mar 2025
deadline12 Mar 2025
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Evolocumab, Atc C10Ax13 For The Period 01.04.2025 - 31.03.2027
country Germany
posting date17 Feb 2025
deadline05 Feb 2027
Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V On The Active Ingredient Evolocumab, Atc C10Ax13 For The Period 01.04.2025 - 31.03.2027
country Germany
posting date17 Feb 2025
deadline05 Feb 2027
Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So-Called Open House Procedure.
country Germany
posting date31 Oct 2024
deadline31 Dec 2026

Share Share this page